International adds Nano Cannabidiol to NanoMyros for
Inhibition of Microvesicle and
Exosome Release in Prostate Cancer
OCEANSIDE, CA -- July
15, 2019 -- InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
TSOI) announced today the
addition of nano particle cannabidiol to NanoMyros in the form of
our proprietary product Nano Cannabidiol.
(also known as CBD) is a phytocannabinoid derived from the cannabis
species, is devoid of psychoactive activity, but has analgesic,
anti-inflammatory, antineoplastic and chemopreventive activities.
Upon administration, cannabidiol (CBD) exerts its
anti-proliferative, anti-angiogenic and pro-apoptotic activity
through various mechanisms.
The addition of "Nano
Cannabidiol" to NanoMyros is
inhibit microvesicles and exosomes from being
of proteins. Microvesicle
transfer of other pro-oncogenic
"This final piece of
this unique synergistic blend of pterostilbene, glucoraphanin,
myrosinase, and now cannabidiol is not available by any other
manufacturer that we are aware of and is built entirely on our nano
products NanoStilbene and Nano Cannabidiol," said Timothy
Dixon, President, and CEO of Therapeutic Solutions International.
"We will offer the
NanoMyros with and without
Cannabidiol so as not to restrict
anyone from the benefits of
and NanoMyros as stand-alone nutraceuticals."
from our collaborators indicates that this combination is effective
at decreasing both production of pathological exosomes, as well as
the responsiveness of target cells to pathological
exosomes," said Thomas Ichim,
Ph.D., Board Member of TSOI. "Specifically, we have
demonstrated that subsequent to treatment of cancer cells using the
combination product, there was both a decrease in the production
bearing exosomes, which are known to kill immune cells, as well as
an increased resistance of immune cells to killing by
bearing exosomes produced by cancer."
About Therapeutic Solutions International,
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or
downregulate (make less active) one's immune system. The Company's
corporate website is www.therapeuticsolutionsint.com
e-commerce at www.youcanordernow.com.
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements